TJC0434

TJC0434 is a preclinical-stage small molecule inhibitor developed by TaiwanJ Pharmaceuticals that targets NADPH oxidase (NOX) enzymes. The mechanism of action focuses on reducing the production of reactive oxygen species (ROS), which are known to drive tumorigenic processes and inflammatory signaling. By inhibiting NOX, TJC0434 aims to interfere with ROS-mediated pathways that contribute to cancer progression. While its primary oncology focus is currently in animal studies, the compound has also been explored for its potential in treating other conditions associated with oxidative stress and inflammation, such as gout. TaiwanJ Pharmaceuticals has secured patents for the compound in several regions, including Taiwan, China, and Japan.